However, the rates of lymph node metastasis and HER-2 positivity were not significantly different from those of ER(-)/PR(-) cancer, and there were no significant differences in these rates compared with ER(+)/PR(-) cancer. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.